View Financial HealthPeak Processing 배당 및 자사주 매입배당 기준 점검 0/6Peak Processing 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-24.9%자사주 매입 수익률총 주주 수익률-24.9%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesBoard Change • May 20High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Matt Adams is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Board Change • May 01High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Matt Adams is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.공시 • Feb 02Peak Processing Limited has completed a Follow-on Equity Offering in the amount of AUD 2.72 million.Peak Processing Limited has completed a Follow-on Equity Offering in the amount of AUD 2.72 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 150,000,000 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Transaction Features: Subsequent Direct Listing공시 • Jan 20Peak Processing Limited Announces Cessation of Employment of Brian Mbesha as CFO, Effective January 20, 2026Peak Processing Limited announced the immediate cessation of employment of its Canadian-based Chief Financial Officer (CFO), Mr. Brian Mbesha, as part of an internal restructure. This change forms part of a broader and ongoing cost optimisation program focused on strengthening financial discipline and supporting improved operational execution. Financial oversight, reporting, and controls will continue uninterrupted, led by the Company’s existing finance team, with additional interim part-time assistance from an experienced Australian-based external professional services firm accustomed to Australian reporting requirements to fulfil the CFO functions and ensure compliance and continuity during this transition period. Effective immediately on January 20, 2026.Board Change • Jan 01High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Matt Adams is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.공시 • Oct 01Althea Group Holdings Limited, Annual General Meeting, Nov 27, 2025Althea Group Holdings Limited, Annual General Meeting, Nov 27, 2025.공시 • Sep 17Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.55 million.Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.55 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 141,666,667 Price\Range: AUD 0.018 Discount Per Security: AUD 0.00108 Security Features: Attached Options Transaction Features: Subsequent Direct ListingReported Earnings • Aug 31Full year 2025 earnings released: AU$0.009 loss per share (vs AU$0.085 loss in FY 2024)Full year 2025 results: AU$0.009 loss per share (improved from AU$0.085 loss in FY 2024). Revenue: AU$15.5m (down 49% from FY 2024). Net loss: AU$4.84m (loss narrowed 85% from FY 2024). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.공시 • Feb 19Althea Group Holdings Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.Althea Group Holdings Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 119,000,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Name: Common Shares Security Type: Common Stock Securities Offered: 6,000,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Transaction Features: Subsequent Direct Listing공시 • Feb 17Althea Group Holdings Limited Appoints Matt Adams as Non-Executive DirectorAlthea Group Holdings Limited announced the appointment of Mr. Matt Adams as a Non-Executive Director, effective 17 February 2025. Mr. Adams is an experienced finance professional with over 25 years of executive-level experience across corporate finance, restructuring, and turnaround sectors. He has held senior leadership positions, including CEO, CFO, and CRO roles for both listed and unlisted entities. He is currently the Managing Director of Dynamic Corporate Investments, a boutique corporate finance firm specialising in restructuring, corporate advisory, and investment. Mr. Adams' extensive background in financial structuring, governance, and risk management will provide valuable strategic insights to AGH as the Company continues to execute its growth initiatives.공시 • Jan 31Althea Group Holdings Limited Announces Penelope Dobson Intention to Retire as DirectorAlthea Group Holdings Limited announced that Penelope Dobson has advised her intention to retire as director at the annual general meeting to be held on January 31, 2025.공시 • Dec 30Althea Group Holdings Limited, Annual General Meeting, Jan 31, 2025Althea Group Holdings Limited, Annual General Meeting, Jan 31, 2025.공시 • Oct 30Montu Group UK Ltd completed the acquisition of MyAccess Clinics business in the UK and Ireland of Althea Group Holdings Limited from Althea Group Holdings Limited (ASX:AGH).Montu Group UK Ltd agreed to acquire MyAccess Clinics business in the UK and Ireland of Althea Group Holdings Limited from Althea Group Holdings Limited (ASX:AGH) for AUD 1 million on October 17, 2024. The completion is subject to the following conditions precedent: Transfer of patient information; Execution of an IP Assignment Deed for the assignment of intellectual property rights o Provision and verification of data relating to patient numbers; Completion will occur 5 business days from the date on which the above conditions have been satisfied (or waived by Montu UK); and The Asset Sale Deed otherwise contains terms customary for a transaction of this nature, including in relation to representations and warranties and and is expected to complete in the coming weeks. Montu Group UK Ltd completed the acquisition of MyAccess Clinics business in the UK and Ireland of Althea Group Holdings Limited from Althea Group Holdings Limited (ASX:AGH) on October 29, 2024.Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.085 loss per share (vs AU$0.039 loss in FY 2023)Full year 2024 results: AU$0.085 loss per share (further deteriorated from AU$0.039 loss in FY 2023). Revenue: AU$30.4m (up 21% from FY 2023). Net loss: AU$32.1m (loss widened 134% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings.공시 • Aug 21Althea Group Holdings Limited Announces Board Changes19 August 2024: Althea Group Holdings Limited announced that Mr. Andrew Newbold will step down from his position as Non- Executive Director and Chairman of the Board on 29 August 2024, following a scheduled board meeting. Mr. Vaughan Webber will then assume the role of Chairman, effective immediately on conclusion of this meeting. Mr. Newbold has served as Non-Executive Director and Chairman since September 2018, providing exemplary leadership and guidance during a period of significant growth and transformation for AGH. The Board extend its sincere thanks to Mr. Newbold for his dedication, strategic vision, and commitment to the Company. We wish him all the best in his future endeavours. The Board announced the appointment of Mr. Vaughan Webber as the new Non-Executive Director and Chairman of Althea Group Holdings Ltd, effective immediately upon Mr. Newbold's resignation on 29 August 2024. Mr. Webber is a seasoned company director and finance executive with over 20 years of experience, possessing an in-depth understanding of ASX-listed company operations and governance. His career highlights include: Non-Executive Director, HUB24 Ltd. (2012-2018): Joined during a board restructure to help recapitalise the business, divest non-performing divisions, and support the CEO and management team in developing a robust strategy. Independent Chairman, Wentworth Holdings Ltd. (2009-2013): Oversaw the company's restructuring, the sale of its primary business operations, and the subsequent acquisition by Thorney Opportunities Ltd.공시 • Jul 17Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.026662 million.Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.026662 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 101,333,100 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Transaction Features: Subsequent Direct ListingNew Risk • Jul 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.2m free cash flow). Earnings have declined by 10% per year over the past 5 years. Market cap is less than US$10m (AU$11.9m market cap, or US$8.02m). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (7.6% increase in shares outstanding).New Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.2m free cash flow). Earnings have declined by 10% per year over the past 5 years. Market cap is less than US$10m (AU$11.5m market cap, or US$7.64m). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (9.7% increase in shares outstanding).공시 • Jan 05Althea Group Holdings Limited, Annual General Meeting, Jan 30, 2024Althea Group Holdings Limited, Annual General Meeting, Jan 30, 2024, at 17:00 AUS Eastern Standard Time. Agenda: To receive the financial statements, Directors's report and auditor's report for the Company for the financial year ended 30 June 2023; to consider the Remuneration Report; to consider the Additional 10% Placement Capacity; to consider the Re-election of Directors; to consider Short Term Incentive - Grant of Performance Rights to Joshua Fegan; to consider the Long Term Incentive - Grant of Performance Rights to Joshua Fegan; and to consider any other business that may be lawfully brought forward.New Risk • Sep 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$7.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$7.8m free cash flow). Earnings have declined by 16% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (AU$15.9m market cap, or US$10.3m).New Risk • Aug 29New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 19% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (AU$16.3m market cap, or US$10.5m).공시 • Jul 24Althea Group Holdings Limited Announces Approval for Althea CBD12:THC10 for Reimbursement in IrelandAlthea Group Holdings Limited announced that Ireland's Primary Care Reimbursement Service (`PCRS') has approved Althea CBD12:THC10 for reimbursement in Ireland. In a follow up to the Company's ASX announcement on 20 May 2022, Althea CBD12:THC10 has now been added to the PCRS in the Republic of Ireland, making it free of charge for Irish patients. The Rapid Review Submission for Althea CBD12:THC10 cannabis oil (50 ml), as included in Schedule 1 of the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2023, has resulted in the assignment of administrative codes to facilitate access to the product in line with the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) Regulations 2019 (as amended) for the specified therapeutic indications below, with an effective date of 1st August 2023: Spasticity associated with multiple sclerosis resistant to all standard therapies and interventions; Intractable nausea and vomiting associated with chemotherapy, despite the use of standard anti-emetic regimes. The agreed reimbursement price for Althea CBD12:THC10 (50ml) is 327.89, or approximately AUD 540. Multiple sclerosis (MS) is a complex inflammatory disease of the central nervous system (CNS). The onset of the disease is typically between 20 to 40 years of age, and up to 9,000 people live with this chronic condition in Ireland. Approximately 70% to 80% of adults with cancer experience chemotherapy-induced nausea and vomiting (CINV). CINV remains one of the most distressing symptoms associated with cancer therapy and is associated with decreased adherence to chemotherapy.New Risk • Jul 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 19% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (AU$16.4m market cap, or US$10.9m).공시 • Feb 03Althea Group Holdings Limited announced that it has received AUD 2.2 million in funding from Obsidian Global Partners, LLCAlthea Group Holdings Limited announced that it has issued unsecured convertible notes for gross proceeds of AUD 2,200,000 on February 3, 2023. The transaction included participation from institutional investor Obsidian Global Partners, LLC. The notes are convertible at a conversion price of $1.5 (AUD 2.1153) into 54,206,846 common shares of the company. The company will pay no interest on the notes. The investor may in its discretion elect to convert one or more convertible securities at the relevant conversion price by providing the company notice, provided that, where an issue of shares would result in the voting power in the company of the investor or any other person exceeding 19.99%.The notes will mature twelve months from the date which is five business days from the date of execution of the relevant agreement. The company also issued 4,800,000 options with an an exercise price equal to 200% of the 5 actual trading days immediately prior to mutual execution of the relevant agreement. The company will pay fee of 6% of the purchase price and AUD 15,000 upfront as legal cost of the transaction.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Non-Executive Director Jakob Ripshtein was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 02Full year 2022 earnings released: AU$0.04 loss per share (vs AU$0.061 loss in FY 2021)Full year 2022 results: AU$0.04 loss per share (up from AU$0.061 loss in FY 2021). Revenue: AU$20.5m (up 78% from FY 2021). Net loss: AU$12.1m (loss narrowed 19% from FY 2021). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Non-Executive Director Jakob Ripshtein was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Feb 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Non-Executive Director Jakob Ripshtein was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Breakeven Date Change • Nov 24No longer forecast to breakevenThe analyst covering Althea Group Holdings no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of AU$5.00m in 2023. New forecast suggests the company will make a loss of AU$100.0k in 2023.Reported Earnings • Sep 02Full year 2021 earnings released: AU$0.06 loss per share (vs AU$0.064 loss in FY 2020)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2021 results: Revenue: AU$11.5m (up 128% from FY 2020). Net loss: AU$15.0m (loss widened 1.9% from FY 2020).Reported Earnings • Mar 02First half 2021 earnings released: AU$0.035 loss per share (vs AU$0.037 loss in 1H 2020)The company reported a solid first half result with improved revenues and control over costs, although losses were not reduced. First half 2021 results: Revenue: AU$5.10m (up 175% from 1H 2020). Net loss: AU$8.27m (flat on 1H 2020).Is New 90 Day High Low • Feb 11New 90-day high: AU$0.57The company is up 30% from its price of AU$0.44 on 13 November 2020. The Australian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 33% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 PKP 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: PKP 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Peak Processing 배당 수익률 vs 시장PKP의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (PKP)n/a시장 하위 25% (AU)2.9%시장 상위 25% (AU)6.9%업계 평균 (Pharmaceuticals)2.3%분석가 예측 (PKP) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 PKP 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 PKP 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 PKP 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: PKP 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YAU 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 19:36종가2026/05/21 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Peak Processing Limited는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullPAC Partners Securities Pty. Ltd.Alexander SmithPAC Partners Securities Pty. Ltd.
Board Change • May 20High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Matt Adams is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Board Change • May 01High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Matt Adams is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
공시 • Feb 02Peak Processing Limited has completed a Follow-on Equity Offering in the amount of AUD 2.72 million.Peak Processing Limited has completed a Follow-on Equity Offering in the amount of AUD 2.72 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 150,000,000 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Transaction Features: Subsequent Direct Listing
공시 • Jan 20Peak Processing Limited Announces Cessation of Employment of Brian Mbesha as CFO, Effective January 20, 2026Peak Processing Limited announced the immediate cessation of employment of its Canadian-based Chief Financial Officer (CFO), Mr. Brian Mbesha, as part of an internal restructure. This change forms part of a broader and ongoing cost optimisation program focused on strengthening financial discipline and supporting improved operational execution. Financial oversight, reporting, and controls will continue uninterrupted, led by the Company’s existing finance team, with additional interim part-time assistance from an experienced Australian-based external professional services firm accustomed to Australian reporting requirements to fulfil the CFO functions and ensure compliance and continuity during this transition period. Effective immediately on January 20, 2026.
Board Change • Jan 01High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Matt Adams is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
공시 • Oct 01Althea Group Holdings Limited, Annual General Meeting, Nov 27, 2025Althea Group Holdings Limited, Annual General Meeting, Nov 27, 2025.
공시 • Sep 17Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.55 million.Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.55 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 141,666,667 Price\Range: AUD 0.018 Discount Per Security: AUD 0.00108 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.009 loss per share (vs AU$0.085 loss in FY 2024)Full year 2025 results: AU$0.009 loss per share (improved from AU$0.085 loss in FY 2024). Revenue: AU$15.5m (down 49% from FY 2024). Net loss: AU$4.84m (loss narrowed 85% from FY 2024). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.
공시 • Feb 19Althea Group Holdings Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.Althea Group Holdings Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 119,000,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Name: Common Shares Security Type: Common Stock Securities Offered: 6,000,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Transaction Features: Subsequent Direct Listing
공시 • Feb 17Althea Group Holdings Limited Appoints Matt Adams as Non-Executive DirectorAlthea Group Holdings Limited announced the appointment of Mr. Matt Adams as a Non-Executive Director, effective 17 February 2025. Mr. Adams is an experienced finance professional with over 25 years of executive-level experience across corporate finance, restructuring, and turnaround sectors. He has held senior leadership positions, including CEO, CFO, and CRO roles for both listed and unlisted entities. He is currently the Managing Director of Dynamic Corporate Investments, a boutique corporate finance firm specialising in restructuring, corporate advisory, and investment. Mr. Adams' extensive background in financial structuring, governance, and risk management will provide valuable strategic insights to AGH as the Company continues to execute its growth initiatives.
공시 • Jan 31Althea Group Holdings Limited Announces Penelope Dobson Intention to Retire as DirectorAlthea Group Holdings Limited announced that Penelope Dobson has advised her intention to retire as director at the annual general meeting to be held on January 31, 2025.
공시 • Dec 30Althea Group Holdings Limited, Annual General Meeting, Jan 31, 2025Althea Group Holdings Limited, Annual General Meeting, Jan 31, 2025.
공시 • Oct 30Montu Group UK Ltd completed the acquisition of MyAccess Clinics business in the UK and Ireland of Althea Group Holdings Limited from Althea Group Holdings Limited (ASX:AGH).Montu Group UK Ltd agreed to acquire MyAccess Clinics business in the UK and Ireland of Althea Group Holdings Limited from Althea Group Holdings Limited (ASX:AGH) for AUD 1 million on October 17, 2024. The completion is subject to the following conditions precedent: Transfer of patient information; Execution of an IP Assignment Deed for the assignment of intellectual property rights o Provision and verification of data relating to patient numbers; Completion will occur 5 business days from the date on which the above conditions have been satisfied (or waived by Montu UK); and The Asset Sale Deed otherwise contains terms customary for a transaction of this nature, including in relation to representations and warranties and and is expected to complete in the coming weeks. Montu Group UK Ltd completed the acquisition of MyAccess Clinics business in the UK and Ireland of Althea Group Holdings Limited from Althea Group Holdings Limited (ASX:AGH) on October 29, 2024.
Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.085 loss per share (vs AU$0.039 loss in FY 2023)Full year 2024 results: AU$0.085 loss per share (further deteriorated from AU$0.039 loss in FY 2023). Revenue: AU$30.4m (up 21% from FY 2023). Net loss: AU$32.1m (loss widened 134% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings.
공시 • Aug 21Althea Group Holdings Limited Announces Board Changes19 August 2024: Althea Group Holdings Limited announced that Mr. Andrew Newbold will step down from his position as Non- Executive Director and Chairman of the Board on 29 August 2024, following a scheduled board meeting. Mr. Vaughan Webber will then assume the role of Chairman, effective immediately on conclusion of this meeting. Mr. Newbold has served as Non-Executive Director and Chairman since September 2018, providing exemplary leadership and guidance during a period of significant growth and transformation for AGH. The Board extend its sincere thanks to Mr. Newbold for his dedication, strategic vision, and commitment to the Company. We wish him all the best in his future endeavours. The Board announced the appointment of Mr. Vaughan Webber as the new Non-Executive Director and Chairman of Althea Group Holdings Ltd, effective immediately upon Mr. Newbold's resignation on 29 August 2024. Mr. Webber is a seasoned company director and finance executive with over 20 years of experience, possessing an in-depth understanding of ASX-listed company operations and governance. His career highlights include: Non-Executive Director, HUB24 Ltd. (2012-2018): Joined during a board restructure to help recapitalise the business, divest non-performing divisions, and support the CEO and management team in developing a robust strategy. Independent Chairman, Wentworth Holdings Ltd. (2009-2013): Oversaw the company's restructuring, the sale of its primary business operations, and the subsequent acquisition by Thorney Opportunities Ltd.
공시 • Jul 17Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.026662 million.Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.026662 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 101,333,100 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Transaction Features: Subsequent Direct Listing
New Risk • Jul 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.2m free cash flow). Earnings have declined by 10% per year over the past 5 years. Market cap is less than US$10m (AU$11.9m market cap, or US$8.02m). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (7.6% increase in shares outstanding).
New Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.2m free cash flow). Earnings have declined by 10% per year over the past 5 years. Market cap is less than US$10m (AU$11.5m market cap, or US$7.64m). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (9.7% increase in shares outstanding).
공시 • Jan 05Althea Group Holdings Limited, Annual General Meeting, Jan 30, 2024Althea Group Holdings Limited, Annual General Meeting, Jan 30, 2024, at 17:00 AUS Eastern Standard Time. Agenda: To receive the financial statements, Directors's report and auditor's report for the Company for the financial year ended 30 June 2023; to consider the Remuneration Report; to consider the Additional 10% Placement Capacity; to consider the Re-election of Directors; to consider Short Term Incentive - Grant of Performance Rights to Joshua Fegan; to consider the Long Term Incentive - Grant of Performance Rights to Joshua Fegan; and to consider any other business that may be lawfully brought forward.
New Risk • Sep 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$7.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$7.8m free cash flow). Earnings have declined by 16% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (AU$15.9m market cap, or US$10.3m).
New Risk • Aug 29New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 19% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (AU$16.3m market cap, or US$10.5m).
공시 • Jul 24Althea Group Holdings Limited Announces Approval for Althea CBD12:THC10 for Reimbursement in IrelandAlthea Group Holdings Limited announced that Ireland's Primary Care Reimbursement Service (`PCRS') has approved Althea CBD12:THC10 for reimbursement in Ireland. In a follow up to the Company's ASX announcement on 20 May 2022, Althea CBD12:THC10 has now been added to the PCRS in the Republic of Ireland, making it free of charge for Irish patients. The Rapid Review Submission for Althea CBD12:THC10 cannabis oil (50 ml), as included in Schedule 1 of the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2023, has resulted in the assignment of administrative codes to facilitate access to the product in line with the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) Regulations 2019 (as amended) for the specified therapeutic indications below, with an effective date of 1st August 2023: Spasticity associated with multiple sclerosis resistant to all standard therapies and interventions; Intractable nausea and vomiting associated with chemotherapy, despite the use of standard anti-emetic regimes. The agreed reimbursement price for Althea CBD12:THC10 (50ml) is 327.89, or approximately AUD 540. Multiple sclerosis (MS) is a complex inflammatory disease of the central nervous system (CNS). The onset of the disease is typically between 20 to 40 years of age, and up to 9,000 people live with this chronic condition in Ireland. Approximately 70% to 80% of adults with cancer experience chemotherapy-induced nausea and vomiting (CINV). CINV remains one of the most distressing symptoms associated with cancer therapy and is associated with decreased adherence to chemotherapy.
New Risk • Jul 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 19% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (AU$16.4m market cap, or US$10.9m).
공시 • Feb 03Althea Group Holdings Limited announced that it has received AUD 2.2 million in funding from Obsidian Global Partners, LLCAlthea Group Holdings Limited announced that it has issued unsecured convertible notes for gross proceeds of AUD 2,200,000 on February 3, 2023. The transaction included participation from institutional investor Obsidian Global Partners, LLC. The notes are convertible at a conversion price of $1.5 (AUD 2.1153) into 54,206,846 common shares of the company. The company will pay no interest on the notes. The investor may in its discretion elect to convert one or more convertible securities at the relevant conversion price by providing the company notice, provided that, where an issue of shares would result in the voting power in the company of the investor or any other person exceeding 19.99%.The notes will mature twelve months from the date which is five business days from the date of execution of the relevant agreement. The company also issued 4,800,000 options with an an exercise price equal to 200% of the 5 actual trading days immediately prior to mutual execution of the relevant agreement. The company will pay fee of 6% of the purchase price and AUD 15,000 upfront as legal cost of the transaction.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Non-Executive Director Jakob Ripshtein was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 02Full year 2022 earnings released: AU$0.04 loss per share (vs AU$0.061 loss in FY 2021)Full year 2022 results: AU$0.04 loss per share (up from AU$0.061 loss in FY 2021). Revenue: AU$20.5m (up 78% from FY 2021). Net loss: AU$12.1m (loss narrowed 19% from FY 2021). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Non-Executive Director Jakob Ripshtein was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Feb 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Non-Executive Director Jakob Ripshtein was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Breakeven Date Change • Nov 24No longer forecast to breakevenThe analyst covering Althea Group Holdings no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of AU$5.00m in 2023. New forecast suggests the company will make a loss of AU$100.0k in 2023.
Reported Earnings • Sep 02Full year 2021 earnings released: AU$0.06 loss per share (vs AU$0.064 loss in FY 2020)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2021 results: Revenue: AU$11.5m (up 128% from FY 2020). Net loss: AU$15.0m (loss widened 1.9% from FY 2020).
Reported Earnings • Mar 02First half 2021 earnings released: AU$0.035 loss per share (vs AU$0.037 loss in 1H 2020)The company reported a solid first half result with improved revenues and control over costs, although losses were not reduced. First half 2021 results: Revenue: AU$5.10m (up 175% from 1H 2020). Net loss: AU$8.27m (flat on 1H 2020).
Is New 90 Day High Low • Feb 11New 90-day high: AU$0.57The company is up 30% from its price of AU$0.44 on 13 November 2020. The Australian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 33% over the same period.